Top

Published in:

01-01-2012 | Hepatobiliary Tumors

Preoperative FDG-PET Predicts Recurrence Patterns in Hepatocellular Carcinoma

Authors: Koji Kitamura, MD, PhD, Etsuro Hatano, MD, PhD, Tatsuya Higashi, MD, PhD, Satoru Seo, MD, PhD, Yuji Nakamoto, MD, PhD, Kenya Yamanaka, MD, Taku Iida, MD, PhD, Kojiro Taura, MD, PhD, Kentaro Yasuchika, MD, PhD, Shinji Uemoto, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2012

Abstract

Purpose

We investigated the usefulness of preoperative fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) as a tool for predicting recurrence patterns to select patients for liver resection as an initial surgical strategy for hepatocellular carcinoma.

Methods

Sixty-three consecutive hepatocellular carcinoma patients undergoing FDG-PET were enrolled. They were classified according to the initial recurrence patterns (beyond the Milan criteria [MC], within the MC, and no recurrence) and the time intervals before initial postoperative recurrence (within 1 year, after 1 year or later, and no recurrence). The tumor-to-nontumor ratio (TNR) obtained by FDG-PET and survival rates were compared among the groups.

Results

TNR in the recurrence within the MC group (1.9 ± 1.6) and no recurrence group (1.3 ± 1.5) was significantly lower than that in the beyond the MC group (2.9 ± 2.6). TNR was an independent predictive factor of recurrence patterns in multivariate analysis. TNR in the groups with recurrence after 1 year or later (1.6 ± 0.8) and no recurrence (1.3 ± 0.5) were significantly lower than that in the within 1-year group (3.1 ± 2.7). TNR was an independent predictive factor of the interval before initial recurrence by multivariate analysis.

Conclusions

Preoperative FDG-PET predicts hepatocellular carcinoma recurrences within the MC or no recurrence and recurrences after 1 year or later. FDG-PET may be useful for selecting appropriate patients for liver resection as an initial surgical strategy.

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRef

Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–7.PubMedCrossRef

Jonas S, Herrmann M, Rayes N, et al. Survival after liver transplantation for hepatocellular carcinoma in cirrhosis according to the underlying liver disease. Transplant Proc. 2001;33:3444–5.PubMedCrossRef

Michel J, Suc B, Montpeyroux F, et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol. 1997;26:1274–80.PubMedCrossRef

Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000;190:580–7.PubMedCrossRef

Cherqui D, Laurent A, Mocellin N, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg. 2009;250:738–46.PubMedCrossRef

Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–82.PubMedCrossRef

Taura K, Ikai I, Hatano E, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142:685–94.PubMedCrossRef

Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30:1736–41.PubMedCrossRef

10.

Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13(2 Pt 1):427–33.PubMedCrossRef

11.

Kitamura K, Hatano E, Higashi T, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011 (in press).

12.

Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2009;37:468–82.PubMedCrossRef

13.

Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRef

14.

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRef

15.

Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115–20.PubMedCrossRef

16.

Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–9.PubMedCrossRef

17.

Poon RT, Fan ST, Yu WC, et al. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg. 2001;136:693–9.PubMedCrossRef

18.

Makuuchi M, Takayama T, Kubota K, et al. Hepatic resection for hepatocellular carcinoma—Japanese experience. Hepatogastroenterology. 1998;45(Suppl 3):1267–74.PubMed

19.

Hwang S, Lee SG, Moon DB, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl. 2007;13:741–6.PubMedCrossRef

20.

Vennarecci G, Ettorre GM, Antonini M, et al. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis. Transplant Proc. 2007;39:1857–60.PubMedCrossRef

21.

Kim BW, Park YK, Kim YB, et al. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc. 2008;40:3558–61.PubMedCrossRef

22.

Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 2004;10:1294–300.PubMedCrossRef

23.

Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238:885–92.PubMedCrossRef

24.

Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.PubMedCrossRef

25.

Scatton O, Zalinski S, Terris B, et al. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl. 2008;14:779–88.PubMedCrossRef

26.

Sato F, Hatano E, Kitamura K, et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria. PLoS One. 2011;6:e16435.PubMedCrossRef

27.

Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111:720–6.PubMedCrossRef

28.

Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10.PubMedCrossRef

29.

Matsumata T, Kanematsu T, Takenaka K, et al. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.PubMedCrossRef

Title: Preoperative FDG-PET Predicts Recurrence Patterns in Hepatocellular Carcinoma
Authors: Koji Kitamura, MD, PhD
Etsuro Hatano, MD, PhD
Tatsuya Higashi, MD, PhD
Satoru Seo, MD, PhD
Yuji Nakamoto, MD, PhD
Kenya Yamanaka, MD
Taku Iida, MD, PhD
Kojiro Taura, MD, PhD
Kentaro Yasuchika, MD, PhD
Shinji Uemoto, MD, PhD
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1990-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Preoperative FDG-PET Predicts Recurrence Patterns in Hepatocellular Carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Role of Radiation in Intermediate-Risk Rectal Cancer

Genomic Instability Measured by Inter-(Simple Sequence Repeat) PCR and High-Resolution Microsatellite Instability are Prognostic of Colorectal Carcinoma Survival After Surgical Resection

Incorporation of Adjuvant Therapy into the Multimodality Management of Gastrointestinal Stromal Tumors of the Stomach in the United States

Poorer Prognosis and Higher Prevalence of BRAF V600E Mutation in Synchronous Bilateral Papillary Thyroid Carcinoma

The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with High-Grade Appendiceal Carcinoma and Extensive Peritoneal Carcinomatosis

Does Chemotherapy Prior to Emergency Surgery Affect Patient Outcomes? Examination of 1912 Patients